522 F.Supp.3d 634
N.D. Cal.2021Background
- Walgreens sold two private-label liquid acetaminophen products: "Infants’ Pain & Fever" and "Children’s Pain & Fever." Both prominently list the same concentration, "160 mg per 5 mL," and show dosing devices (syringe on Infants’; cup on Children’s). The Infants’ box states "Ages 2-3 Years"; the Children’s box states "Ages 2-11 Years."
- Industry-wide reformulation in 2011 standardized infant formulations to 160 mg/5 mL; both Walgreens products reflect that concentration on front and in Drug Facts.
- Plaintiff Cameron Eidmann alleged the Infants’ packaging misleads consumers into thinking it is specially formulated for infants, causing consumers to pay a premium; he brought claims under California’s FAL, CLRA, and the UCL (fraudulent, unlawful, unfair prongs).
- Walgreens moved to dismiss; both parties’ requests for judicial notice of FDA materials and the product labels were considered; the labels were incorporated by reference and judicially noticed.
- The court held the reasonable‑consumer test was not satisfied because the labels disclose identical concentration, overlapping age ranges, and an infant-specific dosing syringe; omission and duty‑to‑disclose theories failed for lack of a duty or contrary affirmative statements.
- The court granted dismissal of all claims with prejudice, concluding amendment would be futile given the express, undisputed label disclosures.
Issues
| Issue | Plaintiff's Argument | Defendant's Argument | Held |
|---|---|---|---|
| Whether Infants’ packaging is misleading under FAL/CLRA/UCL (reasonable‑consumer test) | Eidmann: the "Infants" name and separate packaging lead reasonable consumers to believe the product is specially formulated for infants and justify a price premium | Walgreens: labels prominently disclose identical concentration and dosing differences; reasonable consumers would not be misled | Court: Not misleading—labels disclose identical concentration, overlapping ages, and dosing device; reasonable‑consumer test not met; claims dismissed |
| Whether omission theory (failure to disclose identical formulation) is actionable | Eidmann: Walgreens omitted that Infants’ and Children’s products are identical, misleading consumers | Walgreens: no duty to disclose; express label disclosures negate any omission; no fiduciary or exclusive knowledge | Court: Omission claims fail—no contrary affirmative statement and no duty to disclose; dismissal granted |
| Whether UCL unlawful/unfair prongs survive based on alleged predicate violations and pricing complaint | Eidmann: predicate violations under FAL/CLRA support UCL claims; pricing differential evidences injury | Walgreens: predicate fraud claims fail; pricing decisions alone are not actionable absent deception | Court: UCL unlawful/fraudulent/unfair prongs fail because predicate fraud claims fail and pricing alone is non‑actionable |
| Whether leave to amend should be granted | Eidmann: previously amended; could propose facts to cure defects | Walgreens: labels and public records are undisputed; defects are incurable | Court: Denied—amendment would be futile given undisputed label disclosures; dismissal with prejudice |
Key Cases Cited
- Ashcroft v. Iqbal, 556 U.S. 662 (U.S. 2009) (pleading standard for well‑pleaded factual allegations)
- Vess v. Ciba‑Geigy Corp. USA, 317 F.3d 1097 (9th Cir. 2003) (Rule 9(b) heightened pleading for fraud‑based claims)
- Williams v. Gerber Prods. Co., 552 F.3d 934 (9th Cir. 2008) (reasonable‑consumer standard for deceptive food labeling)
- Ebner v. Fresh, Inc., 838 F.3d 958 (9th Cir. 2016) (probability that a significant portion of the consuming public could be misled)
- Navarro v. Block, 250 F.3d 729 (9th Cir. 2001) (Rule 12(b)(6) legal sufficiency standard)
- Parks Sch. of Bus., Inc. v. Symington, 51 F.3d 1480 (9th Cir. 1995) (standards for Rule 12(b)(6) motions)
- Lopez v. Smith, 203 F.3d 1122 (9th Cir. 2000) (leave to amend standard on dismissal)
- Mullins v. Premier Nutrition Corp., 178 F. Supp. 3d 867 (N.D. Cal. 2016) (limitations of side‑panel disclosures; reasonable‑consumer analysis)
- Boris v. Wal‑Mart Stores, Inc., 35 F. Supp. 3d 1163 (C.D. Cal. 2014) (pricing differences are not actionable absent deceptive practices)